SOURCE: Five Star Equities

Five Star Equities

February 15, 2012 08:20 ET

Arena Pharmaceuticals and Human Genome Sciences Continue 2012 Upswing

Five Star Equities Provides Stock Research on Arena Pharmaceuticals & Human Genome Sciences

NEW YORK, NY--(Marketwire - Feb 15, 2012) - Biotech stocks have been on an impressive run in 2012 -- handedly outperforming the Dow Jones industrial average year-to-date. The iShares Nasdaq Biotechnology Index Fund -- which contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals -- is up more than 16 percent this year. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Human Genome Sciences Inc. (NASDAQ: HGSI). Access to the full company reports can be found at:

www.fivestarequities.com/ARNA

www.fivestarequities.com/HGSI

Earlier this month The Food and Drug Administration (FDA) released its much anticipated guidelines for the sale of lower-cost versions of biotechnology drugs, which required studies showing that the generic copies are "highly similar" to the originals, but there are several ways that might be proven. According to market analysis firm Datamonitor, the worldwide market for copies of biotech medicines will grow to $3.7 billion by 2015, from just $243 million in 2010, as more than 30 branded biologics with sales of $51 billion lose patent exclusivity.

Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.fivestarequities.com and get exclusive access to our numerous stock reports and industry newsletters.

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Earlier this month the FDA notified Arena that an Endocrinologic and Metabolic Drugs Advisory Committee meeting to discuss the lorcaserin New Drug Application resubmission will be held in the second quarter of 2012. According to a press release issued by Arena, Lorcaserin is a new chemical entity that is believed to act as a selective serotonin 2C receptor agonist. The serotonin 2C receptor is expressed in the brain, including the hypothalamus, an area believed to be involved in the control of appetite and metabolism.

Human Genome Sciences, Inc. operates as a biopharmaceutical company. Its principal products in development include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: www.fivestarequities.com/disclaimer

Contact Information